New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
12:40 EDTGEVASynageva BioPharma announces 6 month data from extension study of SBC-102
Synageva BioPharma announced six month results from an ongoing extension study of sebelipase alfa in adults with late onset Lysosomal Acid Lipase, LAL, Deficiency at the American Association for the Study of Liver Diseases, AASLD, annual meeting being held in Boston, MA, November 9-13.
News For GEVA From The Last 14 Days
Check below for free stories on GEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
10:38 EDTGEVAHigh option volume stocks: CSTM NOW LLTC GEVA IBKR
Subscribe for More Information
April 8, 2014
10:03 EDTGEVAOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:35 EDTGEVASynageva upgraded at Wedbush
As noted earlier, Wedbush upgraded Synageva to Outperform from Neutral. The firm upgraded the stock based on valuation.Target remains $93.
07:11 EDTGEVASynageva upgraded to Outperform from Neutral at Wedbush

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use